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Abstract  
In order to better define virus isolates from animals with malignant catarrhal fever 
(MCF), segments of three genes of ovine herpesvirus-2 were amplified from 
diagnostic samples representing MCF cases with a range of clinical presentations in 
cattle, including head and eye, alimentary and neurological. The variation within 
each gene segment was estimated by DNA sequencing, which confirmed that the 
newly-annotated Ov9.5 gene was significantly more polymorphic than either of the 
other loci tested (segments of ORF50 and ORF75), with alleles that differed at over 
60% of nucleotide positions. Despite this, the nine Ov9.5 alleles characterized had 
identical predicted splicing patterns and could be translated into Ov9.5 polypeptides 
with at least 49% amino acid identity. This multi-locus approach has potential for use 
in epidemiological studies and in charactering chains of infection. However there was 
no association between specific variants of OvHV-2 and the clinical/ pathological 
presentation of MCF in the cattle analysed.  
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1. Introduction 41 
Gammaherpesviruses (γHV) can replicate in and latently infect lymphoid cell types 42 
and are associated with lymphoproliferative diseases and tumours (Ackermann, 2006; Barton 43 
et al., 2011; Nash et al. 2001). They share similarities of size, sequence and genome 44 
organization.  Evolution within the subfamily Gammaherpesvirinae is reflected in the 45 
colinearity of most γHV genome sequences, with approximately 50 genes considered to be 46 
conserved across the group of fully-sequenced γHV  (McGeoch et al., 2005).  The genes of 47 
most γHV are named with respect to the genome of the prototype virus of this family, 48 
herpesvirus saimiri (HVS), with 75 open reading frames (ORF) numbered from the left of the 49 
genome (Albrecht et al., 1992). These genes encode the components of the virus capsid, 50 
tegument and envelope; proteins involved in replication of the virus genome; regulatory 51 
proteins that control the lytic cycle and latency; and proteins that manipulate the metabolism 52 
of the host to benefit viral replication and persistence. Comparison of HVS with other γHV 53 
shows that each virus carries a complement of virus genes that do not have homologues in the 54 
HVS genome (McGeoch, 2001).  These genes are termed unique genes, although they may be 55 
shared within groups of related viruses. They are annotated by a prefix letter specific to the 56 
virus and are numbered from the left of the genome.  Unique genes in γHV have been 57 
identified by bioinformatic analysis, comparative genomics and by analysis of cDNA or 58 
protein sequences (Albrecht et al., 1992; Coulter et al., 2001; Hart et al., 2007; Hughes et al 59 
2010; Mills et al., 2003; Russell et al., 2013). 60 
Several ruminant gammaherpesviruses of the Macavirus genus (Davison et al., 2009) 61 
are associated with the lymphoproliferative disease malignant catarrhal fever (MCF). The 62 
best studied of these are ovine herpesvirus 2 (OvHV-2) and alcelaphine herpesvirus 1 (AlHV-63 
1). MCF occurs when virus shed in the mucous secretions of reservoir host species (sheep for 64 
OvHV-2 and wildebeest for AlHV-1), which are infected efficiently and without obvious 65 
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clinical signs, infects susceptible species such as cattle, bison, deer and pigs (Russell et al., 66 
2009).  MCF is an often-fatal systemic disease that is generally sporadic, affecting individual 67 
animals within a group, but can occasionally cause losses of up to 40% of a herd (Russell et 68 
al., 2009; World Organisation for Animal Health (OIE), 2008). The clinical signs of MCF can 69 
be varied and several distinct disease presentations have been described, including peracute, 70 
head and eye, alimentary and neurological (World Organisation for Animal Health (OIE), 71 
2008). Most MCF cases in cattle present with fever, depression and lymphadenopathy; while 72 
the common head and eye form is further characterized by  nasal and ocular secretions, 73 
corneal opacity, skin lesions and multifocal necrotic lesions of the gums, tongue and palate 74 
(Otter et al., 2002).  In the peracute form, sudden death may occur, though depression 75 
followed by diarrhoea, with death occurring within a few days has also been reported. In the 76 
alimentary form, haemorrhagic diarrhoea may also be found (Holliman et al., 2007), while 77 
nervous signs, ataxia, and blindness have been reported in the neurological form (Mitchell 78 
and Scholes, 2009).  Although MCF is generally considered a disease with a case fatality rate 79 
approaching 100 %, reports of recovery from clinical MCF and chronic infection have also 80 
been published (Milne and Reid, 1990; O’Toole et al., 1997; Penny, 1998; Twomey et al., 81 
2002).  82 
 The genomes of AlHV-1(Ensser et al., 1997) and OvHV-2 (Hart et al., 2007; Taus et 83 
al., 2007; Jayawardane et al., 2008) have been fully sequenced, demonstrating conservation 84 
of γHV genome structure and possession of a similar complement of unique genes (Russell et 85 
al., 2009).  Recently, analysis of virus gene expression in AlHV-1 infected cells revealed the 86 
presence of a novel spliced gene (Russell et al., 2013) that encoded a secreted glycoprotein. 87 
This gene, termed A9.5, had not been previously predicted because of the small size of the 88 
coding exons and because no similar protein was present on any database. Predicted segments 89 
of protein sequence with similarity to these exons were found at the same position in OvHV-90 
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2, such that the homologous gene Ov9.5 could be identified despite having only 33 % 91 
translated amino acid identity to the A9.5 polypeptide.  Notably, the two published OvHV-2 92 
genome sequences contained distinct Ov9.5 genes, which had equivalent positions and 93 
predicted splicing patterns but shared only 60 % nucleotide identity (Russell et al., 2013).  94 
The low degree of identity between the two alleles of Ov9.5 suggests distinct histories, 95 
selective regimes or functions (Russell et al., 2013).  It may therefore be relevant that one 96 
Ov9.5 sequence was from a clinical case of MCF in a British cow while the other was 97 
obtained from OvHV-2 virions from sheep nasal secretions in the USA (Hart et al., 2007; 98 
Taus et al., 2007).  99 
In order to compare sequence variation within the Ov9.5 gene with other loci in 100 
OvHV-2, two additional genes were selected for comparative sequence analysis. These were: 101 
a segment of the ORF75 gene, encoding the virion enzyme formylglycineamide ribotide 102 
amidotransferase (FGARAT), routinely used as the target of a diagnostic PCR assay for 103 
OvHV-2 (Baxter et al., 1993); and a segment of the ORF50 gene, encoding RTA, a 104 
transcription factor involved in lytic cyle activation, selected because of its important role in 105 
virus regulation. The ORF73 (latency-associated nuclear antigen) locus was also considered 106 
as a target for PCR but initial studies showed that this gene could not be reliably amplified 107 
from clinical case material despite the use of published primer sets (Coulter and Reid, 2002) 108 
or newly designed nested primers (GC Russell, unpublished data). This is likely to be a 109 
consequence of the size and repetitive nature of this gene combined with the relatively low 110 
viral load in the samples used for analysis. 111 
In this paper we analyse genetic variation in OvHV-2 from clinical case samples by 112 
looking at three loci to address the hypothesis that the highly polymorphic Ov9.5 gene is a 113 
useful epidemiological marker of OvHV-2 strain variation.  We also examine the possibility 114 
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that distinct strains of OvHV-2 may be responsible for different presentations of MCF in 115 
cattle. 116 
  117 
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2 Materials and methods 118 
2.1. Clinical samples 119 
All DNA samples used in this work were extracted from material submitted to 120 
Moredun Research Institute for PCR-based testing in support of a diagnosis of MCF. Prior to 121 
2006, DNA samples were purified from peripheral blood mononuclear cells (PBMC) or from 122 
tissues from MCF-suspect cases by a standard phenol-based method (Sambrook et al. 1989), 123 
while samples collected since 2006 were purified by a column-based method that did not use 124 
organic solvents (DNeasy mini, Qiagen, Crawley, UK).   125 
OvHV-2 positive samples were selected according to reported clinical signs, 126 
representing a range of clinical disease presentations as documented in Table 1 and 127 
summarised as follows: alimentary, 11 cases, including herds A and E from the report by 128 
Holliman et al. (2007); head & eye, four recovered cases described by Twomey et al. (2002); 129 
neurological, two cases reported by Mitchell and Scholes (2009). In addition, seven DNA 130 
samples from two MCF outbreaks (head and eye form) in different parts of the UK (including 131 
one sample from an in-contact sheep) and five samples from sporadic MCF cases (where no 132 
other MCF-positive sample was submitted from the same source within at least a month) 133 
were analysed (Table 1). As a positive control for the PCR and sequencing reactions, DNA 134 
from the cell line BJ1035 was tested with all primer sets. The OvHV-2 genome from this cell 135 
line was previously sequenced (Hart et al., 2007). 136 
2.2. Amplification and sequencing of selected OvHV-2 gene segments 137 
Primers for nested PCR of the Ov9.5 gene were designed to target conserved areas flanking 138 
the predicted coding region, based on the available sequences of OvHV-2 (Hart et al., 2007; 139 
Taus et al., 2007; Fig. 1; supplementary Fig. S1).  Primers for nested amplification of ORF50 140 
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were chosen within exon 2, to amplify a fragment of 400-500 base pairs for sequence 141 
analysis, and primers for amplification of ORF75 were as described previously (Baxter et al., 142 
1993). Primer pairs were designed using Primer3 (www .bioinformatics.nl/cgi-143 
bin/primer3plus/primer3plus.cgi; Untergasser et al., 2007) and are detailed in Table 2.  144 
ORF50, ORF75 and Ov9.5 gene segments were amplified from genomic DNA 145 
samples in which OvHV-2 DNA had been detected by diagnostic nested PCR (Baxter et al. 146 
1993) or real-time PCR (Hussy et al., 2001). For each gene, first-round amplification was 147 
performed in 25 μl reactions using 1 unit KOD Hot Start DNA polymerase (Merck, Feltham, 148 
UK), 50-100 ng of genomic DNA, and 5 pmol each of the appropriate first round primer set. 149 
Amplification reactions consisted of a denaturation/activation step at 94 °C for 30s; 30 cycles 150 
of 94 °C for 30s, 55 °C for 30 s and 68 °C for 60 s; and a final extension step at 68 °C for 5 151 
minutes. Aliquots of 2 μl from each first round PCR were then used as template in second 152 
round PCR amplifications using the same enzyme, buffer and PCR conditions but with 10 153 
pmol per reaction of the appropriate nested primers. The nested PCR products were analysed 154 
by agarose gel electrophoresis, stained with SYBR®Safe DNA Gel Stain (Life Technologies, 155 
Paisley, UK) and visualized by UV transillumination before purification (QIAamp PCR 156 
purification system). PCR product concentrations were estimated after purification using a 157 
Nanodrop spectrophotometer (Labtech, Uckfield, UK).  Approximately 300 ng of each PCR 158 
product was submitted for bidirectional nucleotide sequencing by Eurofins MWG Operon 159 
(Ebersberg, Germany), using the internal PCR primers as the sequencing primers.  160 
Electropherograms from each pair of sequencing reactions were assembled to produce sample 161 
consensus sequences for each gene segment amplified. 162 
To confirm that direct sequencing of PCR products produced an accurate 163 
representation of the target sequence in vivo, PCR products of Ov9.5 from 5 samples were 164 
cloned into pGEM-T-Easy (Promega, Southampton, UK) and at least three clones 165 
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representing each PCR product were sequenced. The PCR products that were sequenced after 166 
cloning are indicated in Table 1.  167 
2.3. Bioinformatics 168 
Unless otherwise indicated all DNA sequence analysis was done using DNASTAR 169 
Lasergene software (V8.0 and above; www.DNASTAR.com). DNA sequence information 170 
from each amplicon was assembled using the SEQMAN program and consensus sequences 171 
representing the region flanked by the inner nested PCR primers were derived.  Any DNA 172 
sample that did not give good quality sequence traces on both strands for the entire region 173 
was discarded. 174 
The consensus sequences for each sample and locus were aligned using Lasergene 175 
MEGALIGN and MAFFT (Katoh and Standley, 2013; 176 
http://mafft.cbrc.jp/alignment/software/). For Ov9.5,  the positions of introns and exons were 177 
defined according to the annotation of Ov9.5*01 (Russell et al., 2013) and conservation of 178 
splice donor and acceptor sequences was confirmed by visual inspection, while the 179 
conservation of a continuous Ov9.5 open reading frame was confirmed by in silico generation 180 
of predicted Ov9.5 cDNA sequences and their translation.  Phylogenetic and evolutionary 181 
analysis of all sequences was done by maximum likelihood methods using the programs 182 
TOPALi  (Milne et al., 2009; www.topali.org) and MEGA (version 5 or above; Tamura et al., 183 
2011; megasoftware.net).  184 
2.4 Nucleotide sequence accession numbers 185 
Nucleotide sequences of the gene fragments amplified in this work have been 186 
submitted to the European Nucleotide Archive (ENA; www.ebi.ac.uk/ena) and have been 187 
assigned accession numbers as follows.   188 
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For Ov9.5: Ov9.5*0101, HG813097; Ov9.5*0201, HG813098; Ov9.5*0202, 189 
HG813099; Ov9.5*0203, HG813100; Ov9.5*0301, HG813102; Ov9.5*0401, HG813101; 190 
Ov9.5*0501, HG813103; Ov9.5*0502, HG813104; Ov9.5*0503, HG813105.  191 
For OvHV-2 ORF50: ORF50*0101, HG813085; ORF50*0102, HG813086; 192 
ORF50*0103, HG813087; ORF50*0201, HG813088; ORF50*0301, HG813089; 193 
ORF50*0401, HG813090; ORF50*0501, HG813091.  194 
For OvHV-2 ORF75: ORF75*0101, HG813093; ORF75*0102, HG813094; 195 
ORF75*0201, HG813095; ORF75*0301, HG813096. 196 
 197 
3. Results 198 
3.1 Amplification and sequencing of OvHV-2 loci from MCF case samples 199 
Amplification of the ORF75 gene segment routinely used for OvHV-2 diagnostic 200 
PCR used the published primer sequences (Baxter et al., 1993); whilst the ORF50 gene 201 
segment was amplified using novel primers specifically designed for this work. The 202 
sequences of all primers used here are given in Table 2. 203 
To allow conserved primer sites flanking the Ov9.5 gene to be identified, the 204 
intergenic region between the annotated Ov9 and Ov10 genes in the sequenced OvHV-2 205 
isolates from the UK and US (Hart et al., 2007; Taus et al., 2007) was aligned (Fig. 1; 206 
supplementary Fig. S1). This demonstrated that while the predicted Ov9.5 gene was 207 
divergent between the two sequenced virus isolates, with about 60 % nucleotide identity, the 208 
intergenic regions flanking Ov9.5 (approximately 150 bases at the left end and 600 bases at 209 
the right end; Fig. 1) were well-conserved, with greater than 90 % nucleotide identity. The 210 
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Ov9.5-specific primers in Table 2 were placed in conserved flanking regions to allow 211 
amplification of the predicted Ov9.5 coding sequence for studies of genetic variation.   212 
Amplification of the OvHV-2 ORF50, ORF75 and Ov9.5 gene segments was 213 
attempted in DNA samples from 46 OvHV-2 infected animals, including different host 214 
species, MCF presentations, sporadic cases and outbreak samples. Despite the use of nested 215 
PCR, not all samples tested yielded a single clear band of the expected size for each 216 
amplification reaction. This is likely to be a reflection of the age or poor quality of some of 217 
the DNA samples (particularly those that were purified by phenol extraction) leading to 218 
degradation of the DNA or reduced PCR performance but it is also possible that variation 219 
within the primer sites could account for the lack of amplification in some cases. A number 220 
of the samples selected derived from published work describing unusual clinical 221 
presentations of MCF (Holliman et al., 2007; Mitchell and Scholes, 2009; Twomey et al., 222 
2002) and some of these were over ten years old. Assays of failed samples were repeated at 223 
least once for confirmation. Purified PCR products were subject to DNA sequencing using 224 
the inner nested primers from each locus (Table 2). 225 
Samples from five animals were also analysed by cloning of the Ov9.5 PCR product 226 
and subsequent sequencing of multiple clones for each sample (Table 1).  This confirmed that 227 
the consensus sequences obtained by direct sequencing of PCR products were identical to the 228 
sequences of cloned PCR products. Among these Ov9.5 samples, we obtained ten clones that 229 
had been amplified with the outer L1 and R1 primers and 5 clones amplified with the L2-R1 230 
primers (Table 2). These contained the expected sequences at internal primer sites and 231 
showed the same conservation of the region outside the Ov9.5 coding region as the published 232 
genome sequences. These observations support the view that the degree of conservation 233 
around the primer sites, even between highly divergent alleles of Ov9.5, is such that our 234 
nested PCR protocol should be productive in the vast majority of cases. 235 
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3.2 Gene sequence variation in samples from MCF cases  236 
ORF50 sequences were obtained from 25 samples, representing seven different alleles 237 
(Table 3). The majority allele was found in 11 samples and was designated ORF50*0101. 238 
Two smaller groups of samples had sequences that differed by single synonymous nucleotide 239 
substitutions from ORF50*0101 and were called ORF50*0102 and ORF50*0103. Four other 240 
ORF50 alleles encoded different polypeptide sequences: ORF50*0201 and ORF50*0301, 241 
which differed from the majority allele by single amino acid substitutions; and ORF50*0401 242 
and ORF50*0501, each of which had 3 amino acid substitutions compared with ORF50*0101 243 
(Table 3). The sequenced OvHV-2 genomes encoded ORF50*0401 (Hart et al., 2007), 244 
analysed here as the positive control sample BJ1035, and an allele that differed from 245 
ORF50*0101 by two amino acid substitutions, which was not found in our sample set 246 
(designated ORF50*0601 by us; Taus et al., 2007). 247 
ORF75 sequences were obtained from 22 samples. These sequences represented 4 248 
alleles, which differed at up to two nucleotide positions (Table 3). The majority allele was 249 
found in 18 samples and was identical to the ORF75 fragment sequence in one of the two 250 
published OvHV-2 genome sequences (Taus et al., 2007). This allele was named 251 
ORF75*0101. The remaining ORF75 alleles differed by a synonymous nucleotide 252 
substitution in allele ORF75*0102; and by single amino acid changes in alleles ORF75*0201 253 
and ORF75*0301 (Table 3).  254 
Nine different Ov9.5 sequences were obtained from 39 samples (Table 3) representing 255 
5 major clades of alleles that shared 55-99% nucleotide identity (Fig. 2). All of the sequences 256 
obtained had identical patterns of predicted splice donor and acceptor sites and the predicted 257 
spliced cDNAs could encode proteins of approximately 160 residues that shared 50-100 % 258 
translated amino acid identity. The alleles were named by similarity to the previously 259 
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identified Ov9.5 gene variants encoded in the sequenced OvHV-2 genomes (Russell et al., 260 
2013):  Ov9.5*0101 (previously Ov9.5*01; Hart et al., 2007); and Ov9.5*0201 (previously 261 
Ov9.5*02; Taus et al., 2007). Of the 39 Ov9.5 amplicons sequenced, two were identical to 262 
the Ov9.5*0101 sequence and 20 were identical to the Ov9.5*0201 sequence (Table 3). The 263 
remaining 17 sequences included two alleles that were over 99% identical to Ov9.5*0201, 264 
called Ov9.5*0202 and Ov9.5*0203, and three groups of more divergent sequences. These 265 
included Ov9.5*0301, which had 78 % amino acid identity to Ov9.5*0201, and Ov9.5*0401, 266 
with 95 % identity to Ov9.5*0201. The final three alleles encoded Ov9.5 proteins that were 267 
more than 98 % identical to each other but 50-56 % identical to the proteins encoded by the 268 
other allele groups. These were termed Ov9.5*0501 to *0503 (Fig. 2; Table 3).  269 
 270 
3.3 Analysis of Ov9.5 alleles 271 
The Ov9.5 polypeptides encoded by the nine sequence variants in Table 3 were 272 
identical at only 57 positions in the aligned 159 residues. The conserved positions included 273 
seven asparagine residues, of which six were predicted to be potential N-linked glycosylation 274 
sites in at least one variant, and seven cysteine residues. (Fig. 3). These features suggest 275 
shared structural and potentially functional similarity within the Ov9.5 proteins. Structure-276 
based homology searching with an alignment of the available A9.5 and Ov9.5 polypeptide 277 
sequences (http://toolkit.tuebingen.mpg.de/hhpred) showed that only two proteins of known 278 
structure gave significant alignments with the mature Ov9.5 polypeptide sequences. These 279 
were IL-4 (P = 0.001) and IL-21 (P = 0.006), which had previously been identified as 280 
potential homologues of A9.5 (Russell et al., 2013), using an alignment with fewer alleles. 281 
These cytokines share a 4-helix bundle structure stabilised by 3 disulphide bonds. Notably, 282 
among over 100 residues of each cytokine aligned with the A9.5/Ov9.5 sequences, 3 283 
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cysteines were conserved, adding further weight to the hypothesis that these viral genes 284 
encode distant homologues of 4-helix bundle cytokines.  285 
The possibility of positive selection for polymorphism within the Ov9.5 polypeptide 286 
was investigated by analysing the ratio of synonymous to non-synonymous substitutions 287 
within the aligned codons by multiple approaches using Topali and MEGA. Within Topali, 288 
PAML/CodeML (Yang, 2007) was used to test for the presence of positive selection under 289 
three pairs of models with increasing complexity (M0 v M3, M1a v M2a and M7 v M8). In 290 
each case the likelihood ratio test statistic did not reach significance levels. Similarly, using 291 
the Hyphy software package (Kosakovsky Pond et al. 2005) within MEGA, 15 codon 292 
positions had dN-dS values greater than one and the maximum dN-dS value found was 2.0, 293 
but no positions were found to be statistically significant (P<0.05). Thus, there was no 294 
evidence to reject the null hypothesis of neutral selection. However, application of a specific 295 
test of neutrality within MEGA (codon-based Z-test of selection; Nei and Gojobori, 1986), 296 
suggested that the differences between the more divergent alleles (i.e. pairwise comparisons 297 
with less than 90 % identity) could not be explained by neutral selection (P<0.001). 298 
 299 
3.4 Combined phylogenetic analysis 300 
Phylogenetic analysis of the combined ORF50, ORF75 and Ov9.5 nucleotide 301 
sequences from the 21 animals for which data were available from all three loci showed 302 
twelve distinct viral variants (Fig. 4). The overall tree topology was driven by variation 303 
within the Ov9.5 locus, while differences at the other two loci influenced the subdivision of 304 
nodes sharing the same Ov9.5 allele.  Virus genotypes have been assigned in Fig. 4 based on 305 
the Ov9.5 clades and subtypes based on allelic differences at all three loci. The most frequent 306 
genotype among the OvHV-2 strains analysed was OvHV-2 type 2a (ORF50*0101/ 307 
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ORF75*0101/ Ov9.5*0201), which carries the majority allele at each locus. Samples that 308 
shared an Ov9.5 genotype but differed at other loci generally differed at a single locus. Thus 309 
the seven samples with the Ov9.5*0301 allele also shared the ORF75*0101 allele but differed 310 
at ORF50. These small differences between virus genotypes suggest the major mode of 311 
evolution is by sequence divergence whilst recombination between virus genotypes may play 312 
a minor role. 313 
 314 
4. Discussion 315 
In this study, we have analysed OvHV-2 strain variation by sequencing of three loci 316 
in diagnostic samples from 45 infected animals, including sheep, bison, reindeer and cattle. 317 
The analysis showed that there were seven ORF50 alleles, four ORF75 alleles and nine Ov9.5 318 
alleles in our sample set. The degree of polymorphism varied between the genes analysed: 319 
alleles of ORF50 and ORF75 shared greater than 98 % identity whilst the most divergent 320 
alleles of Ov9.5 had around 55 % nucleotide identity (Table 3). These three gene segments 321 
comprise only about 1 % of the OvHV-2 genome. Comparative analysis of the published 322 
OvHV-2 genome sequences (Hart et al., 2007; Taus et al., 2007) showed that there were only 323 
two segments in the genome where sequence identity between the two virus strains was 324 
significantly lower than 98 % (Taus et al., 2007; G.C. Russell unpublished observations). 325 
These were the repetitive region of ORF73, which had segments of identity ranging from 70-326 
90%, and the Ov9.5 gene, which had about 60 % identity between the two genome 327 
sequences. Thus selection of two loci with over 98 % identify between alleles, in addition to 328 
the divergent Ov9.5 region, allowed both the overall conservation between OvHV-2 strains 329 
and the diversity at Ov9.5 to be analysed.  330 
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Although much of the variation in Ov9.5 was found within the predicted intron 331 
sequences (Fig. 1; supplementary Fig. S1), the predicted Ov9.5 spliced cDNA sequences 332 
were also highly polymorphic with 62 % nucleotide and only 50 % predicted amino acid 333 
identity between the coding regions of the most divergent sequences. While no statistical 334 
support was found for positive selection within the Ov9.5 alleles, a null hypothesis of neutral 335 
selection among the more divergent alleles was also rejected. Given that polymorphic sites 336 
are found throughout the Ov9.5 gene (exons and introns), and appear to be restricted to the 337 
Ov9.5 locus, there may be multiple processes driving polymorphism within these alleles,  338 
including, but not limited to, immunological selection acting on Ov9.5 within the reservoir 339 
host. Data from a wider range of Ov9.5 alleles, from MCF cases and reservoir hosts, is 340 
required to allow a deeper analysis of polymorphism in this region. 341 
It is also notable that the Ov9.5*0201 allele, originally identified in sheep samples 342 
from the US (Taus et al., 2007), was the most frequent allele among the samples tested here 343 
(20 of 39 samples). While this indicates that OvHV-2 strains prevalent in Europe and 344 
America may be similar, it also suggests that the characterised genomic sequence of BJ1035 345 
(Hart et al., 2007) represents an infrequent and divergent Ov9.5 genotype. However, the two 346 
strains of virus sequenced to date are highly similar across the remainder of the genome 347 
(Taus et al., 2007) 348 
Despite the highly divergent nature of the Ov9.5 alleles, sequencing of segments of 349 
the ORF50 and ORF75 genes of virus strains carrying the same Ov9.5 alleles showed further 350 
genetic differences. This suggests that while analysis of polymorphism at the Ov9.5 locus 351 
may be a useful tool for distinguishing MCF virus strains, a multi-locus approach may be  352 
more informative for molecular epidemiology of MCF, and for tracing specific chains of 353 
infection.  354 
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The use of Ov9.5 and other loci as genotyping tools for MCF outbreaks is illustrated 355 
in Table 1. Among five outbreaks (outbreak B and outbreak L with head & eye presentation; 356 
farm A, farm E and outbreak A with alimentary presentation; Table 1), cattle involved in four 357 
shared the same Ov9.5 genotype (Ov9.5*0201) suggesting that a single strain of virus may 358 
have been involved in each of these outbreaks and that analysis of Ov9.5 has epidemiological 359 
value. In two of these outbreaks, two cattle were analysed and found to be identical at all 360 
three loci, further supporting this view.  361 
In the fifth outbreak (Twomey et al., 2002), four cattle samples exhibited three 362 
different Ov9.5 genotypes suggesting infection by multiple OvHV-2 strains. This outbreak 363 
was unusual in that all four animals survived MCF, and was complicated by signs of 364 
concurrent bracken poisoning. Bracken poisoning was suggested to be a predisposing or 365 
trigger factor for MCF in these cattle, and may have increased the susceptibility of the 366 
animals involved, potentially leading to infection by different virus strains. 367 
In one MCF outbreak where a virus-positive nasal swab sample was obtained from an 368 
in-contact sheep (sample 10-530-8, outbreak L; Table 1), the genotype of this virus isolate 369 
differed at all three loci from MCF-affected cattle samples from the same outbreak. This 370 
illustrates that further research is required to define chains of infection in MCF outbreaks and 371 
to determine whether the same range of OvHV-2 strains that circulate in sheep are found in 372 
cattle affected by MCF.  373 
An examination of potential correlations between MCF occurrence or presentation 374 
and virus strain was performed for 32 samples that had been genotyped for Ov9.5 or for all 375 
three loci tested. In the case of Ov9.5 alleles, only Ov9.5*0201, *0301 and *0401 were found 376 
in more than two samples. Ov9.5*0201 was found in 16 samples that were classed as 377 
alimentary or head & eye, whilst Ov9.5*0301 was found in six samples classed as alimentary 378 
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or head & eye, and Ov9.5*0401 was found in three samples of which two were classed as 379 
neurological and the third head & eye. Thus, there seems to be no clear association between a 380 
particular presentation of MCF and the genotype of the virus (with respect to the three genes 381 
analysed) isolated from diagnostic samples but this is limited by the low number of samples 382 
for which both clinical data and genotyping were available. Using geographical information 383 
from each case, the distribution of samples genotyped for Ov9.5 was analysed on a regional 384 
basis, in keeping with maintaining anonymity of sample providers. These data, illustrated in 385 
supplementary Fig. S2, showed that the distribution of MCF cases was in line with the 386 
distribution of sheep in the UK – mainly in the west of the country - and that the genotypes 387 
found in outbreaks appeared to reflect the main alleles in that region.  388 
The occurrence of MCF outbreaks may reflect specific strains of virus that are more 389 
infectious or are shed in greater quantities by infected sheep with the potential to infect 390 
groups of cattle or they may indicate conditions of husbandry, environment or herd genetics 391 
that favour virus transmission. Unfortunately there are insufficient data from the samples 392 
analysed in this report to address these hypotheses and further work is required to compare 393 
MCF viruses involved in disease outbreaks with those that cause sporadic MCF.The high 394 
resolution of the molecular methods described here to discriminate between strains of OvHV-395 
2 may facilitate the epidemiological study of MCF in a wider range of samples and locations.  396 
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Table 1. Details of samples analyzed 498 
   
Genotypes
c
  
Sample
a
 Presentation (outbreak)
b
 Species ORF50 ORF75 Ov9.5 Citation/comment
d
 
09-1280 
 
Cattle *0501 ND ND  
09-1334 
 
Cattle *0102 ND ND  
10-441 
 
Cattle *0101 ND ND  
06-1784 
 
Cattle *0103 *0101 *0503  
09-1058 
 
Cattle *0301 *0101 *0301  
09-1060 
 
Cattle *0201 *0101 *0301  
09-1188 
 
Cattle *0101 *0101 *0201  
09-1197 
 
Cattle *0101 *0101 *0201  
09-986 
 
Cattle *0201 *0101 *0301  
05-1500 
 
Cattle ND *0201 ND  
US virus
e
 
 
sheep *0601 *0101 *0201 Taus et al., 2007 
06-146 Alimentary Cattle ND ND *0201  cloned 
06-202-2 Alimentary Cattle *0101 *0101 *0201  
05-725 Alimentary (Farm A) Cattle *0102 *0101 *0301 Holliman et al., 2007 
05-786-4 Alimentary (Farm A) Cattle *0102 *0101 *0301 Holliman et al., 2007 
06-442-1 Alimentary (Farm E) Cattle ND ND *0201 Holliman et al., 2007 
06-442-2 Alimentary (Farm E) Cattle ND ND *0201 Holliman et al., 2007 
06-443 Alimentary (Farm E) Cattle ND ND *0201 Holliman et al., 2007 
06-235-1 Alimentary (outbreak A) Cattle *0101 ND ND  
06-235-2 Alimentary (outbreak A) Cattle ND ND *0201  
06-235-3 Alimentary (outbreak A) Cattle ND ND *0201  
23 
 
06-235-4 Alimentary (outbreak A) Cattle *0101 *0101 *0201  
BJ1035
f
 Head & Eye Cattle *0401 *0301 *0101 
Hart et al., 2007  
cloned 
01-2021-1 Head & Eye (outbreak B) Cattle ND ND *0201 Twomey et al., 2002 
01-2021-2 Head & Eye (outbreak B) Cattle ND ND *0401 Twomey et al., 2002 
01-2021-3 Head & Eye (outbreak B) Cattle ND ND *0301 Twomey et al., 2002 
01-2021-4 Head & Eye (outbreak B) Cattle ND ND *0301 Twomey et al., 2002 
10-414 Head &Eye (outbreak L)  Cattle ND ND *0201  
10-530-11 Head &Eye (outbreak L)  Cattle ND ND *0201  
10-530-12 Head &Eye (outbreak L)  Cattle ND ND *0201  
10-404 Head &Eye (outbreak L) Cattle *0101 *0101 *0201  
10-415 Head &Eye (outbreak L) Cattle *0101 *0101 *0201  
10-530-8  (outbreak L)  Sheep *0103 *0102 *0502  
10-524 Head &Eye (outbreak S) Cattle *0101 *0101 *0201  
06-1114 Head and Eye cattle ND ND *0201  cloned 
06-1116 Head and Eye cattle ND ND *0501  cloned 
01-392 Neurological Cattle ND ND *0401 
Mitchell and Scholes, 
2009 
01-393 Neurological Cattle *0101 *0101 *0401 
Mitchell and Scholes, 
2009 
06-486 (outbreak) cattle ND ND *0201  cloned 
07-1778-2 (Sporadic) Cattle ND ND *0101  
06-1811 (Sporadic) Reindeer *0103 *0101 *0203  
06-283 (Sporadic) Bison *0101 *0101 *0301  
08-145 (Sporadic) Deer *0103 *0101 ND  
06-1567 head & eye (Sporadic) Cattle *0102 *0101 *0301  
24 
 
05-1513 head & eye (Sporadic) Cattle *0102 *0201 *0202  
06-387 
 
cattle ND ND *0201  cloned 
 
499 
a  
Sample identifiers are mainly as assigned by MRI virus surveillance unit, with the format 500 
yy-nnnn-ss, where the first two digits indicate year after 2000 and the following digits are 501 
sample (and sub-sample) number within that year. Exceptions are the samples used for 502 
genome sequencing of OvHV-2: identified as BJ1035 (Hart et al., 2007) and US virus (Taus 503 
et al., 2007). 504 
b
 information on the presentation of MCF in a specific case is given only if recorded. Where 505 
samples were known to be submitted from an outbreak of MCF involving multiple cases with 506 
the same presentation, this is detailed in parentheses. Where no other MCF-positive sample 507 
was submitted from the same source within at least a month, samples are indicated as 508 
sporadic.   509 
c
 genotypes of each locus are given as assigned in the text. ND indicates that the appropriate 510 
PCR product sequence could not be determined from that sample. 511 
d
 where samples analysed here have been described or sequence data presented in previous 512 
publications, these are cited. Those samples for which the Ov9.5 PCR product was 513 
additionally cloned and sequenced from multiple clones are also indicated in this column.   514 
e
 the genotype of each locus from the US virus was assigned based on the predicted PCR 515 
products from the published sequence (Taus et al., 2007).  516 
f
 BJ1035 DNA was analysed as a positive control, confirming the published sequence for the 517 
three loci amplified. 518 
 519 
 520 
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Table 2. PCR primers used in this work 521 
Primer name Sequence (5’-3’) Product size (bp|) Description/reference 
Ov9.5 L1 AAAGACACATGCATCAAACTCT  3’-end of the Ov9.5 putative gene 
Ov9.5 R1 GGGTAAGTACATGGTATAAAGCAG 954 5’-end of the Ov9.5 putative gene 
Ov9.5 L2 TGAAAAACTGGCCACATAAA  nested primer for Ov9.5 L1-R1 product 
Ov9.5 R2 AAGAACCCTGATAAACTCCAGA 893 nested primer for Ov9.5 L1-R1 product 
    
OHVorf50_F1 CCCCAACAAGTCAGCATTTT  ORF50 exon 2 forward 
OHVorf50_R1 TCAGTCGAATGCTGTTGGAG 600 ORF50 exon 2 reverse 
OvHV2_orf50_F2 GGACCTCTCATCTCTTCTGCAA  nested primer for OHVorf50_F1-R1 product 
OvHV2_orf50_R2 ATGGCAAAGTCACAGGGATG 444 nested primer for OHVorf50_F1-R1 product 
    
556 TTCTGGGGTAGTGGCGAGCGAAGGCTTC  Baxter et al., 1993 
755  AAGATAAGCACCAGTTATGCATCTGATAAA 422  
556 TTCTGGGGTAGTGGCGAGCGAAGGCTTC   
555 AGTCTGGGTATATGAATCCAGATGGCTCTC 238  
 522 
523 
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Table 3. Sequence similarity between alleles of the three loci analysed 524 
ORF50 ORF75 Ov9.5 
Alleles 
a 
Differences from 
ORF50*0101 
DNA (protein) 
b 
Number of 
samples of 
each type 
Alleles 
a 
Differences 
from 
ORF75*0101 
DNA (protein) 
b 
Number of 
samples of 
each type 
Alleles 
c 
% identity with 
Ov9.5*0201 
DNA (protein) 
b 
Number of 
samples of 
each type 
ORF50*0101 0 (0) 11 ORF75*0101 0 (0) 18 Ov9.5*0101 56.6 (49.6) 2 
ORF50*0102 1 (0) 5 ORF75*0102 1 (0) 1 Ov9.5*0201 100 (100) 20 
ORF50*0103 1 (0) 4 ORF75*0201 2 (1) 2 Ov9.5*0202 99.7 (99.3) 1 
ORF50*0201 2 (1) 2 ORF75*0301 2 (1) 1 Ov9.5*0203 99.6 (99.3) 1 
ORF50*0301 2 (1) 1    Ov9.5*0301 83.2 (78.6) 9 
ORF50*0401 5 (3) 1    Ov9.5*0401 98.2 (95.5) 3 
ORF50*0501 4 (3) 1    Ov9.5*0501 60.5 (50.6) 1 
ORF50*0601 2 (2) 0    Ov9.5*0502 60.4 (49.6) 1 
      Ov9.5*0503 60.5 (51.2) 1 
 525 
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a
 For ORF50 and ORF75 the number of differences of each allele from the majority allele (*0101) in the DNA sequence is given, with differences in 526 
the translated protein sequence in parentheses.  527 
b
 For each allele of each gene, the number of samples analysed with that allele is given. 528 
c
 For Ov9.5, the percent identity of each allele to the majority allele (Ov9.5*0201) in the DNA and the translated protein sequences are given.529 
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Figure Legends 530 
Fig. 1. Schematic depiction of similarity between the two OvHV-2 genome sequences in the Ov9–531 
Ov10 intergenic region, based on the sequence alignment in supplementary Fig. S1.  Identical 532 
nucleotide positions within the alignment are indicated by vertical bars (|) and mismatched bases are 533 
depicted as dots (.).  The positions of PCR primers designed to amplify the Ov9.5 region are 534 
indicated above the line, with primer names and polarities given. The predicted termination codons 535 
of the Ov9, Ov9.5 and Ov10 genes are shown as colon triplets (:::) annotated above the line, while 536 
the positions of the putative coding exons of the Ov9 5 gene are shaded dark grey within the 537 
alignment and named above it. The region encoding the Ov9.5 gene, which has less than 70% 538 
identity, is highlighted grey, whilst the intergenic flanking regions have over 90% sequence 539 
identity. 540 
 541 
Fig. 2. Phylogenetic analysis of Ov9.5 gene sequences.  Nucleotide sequences of the 9 variants 542 
Ov9.5*0101 to Ov9.5*0503 were aligned using MAFFT and phylogenetic analysis was done in 543 
MEGA version 6.0, using the maximum likelihood approach with 500 bootstrap replicates. Model 544 
selection indicated that the Tamura-Nei model (Tamura and Nei, 1993 ) was most appropriate to 545 
this dataset, producing tree topology that was supported by bootstrap values of least 98 % (except 546 
for the branching within the Ov9.5*05 clade). Bootstrap percentage values are given on the left of 547 
their respective nodes. The tree is drawn to scale, with branch lengths measured in the number of 548 
substitutions per site (with scale bar) .  549 
Fig. 3. Alignment of the Ov9.5 predicted polypeptide sequences aligned by MAFFT 550 
(http://mafft.cbrc.jp/alignment/server/index.html). Conserved residues are indicated below the 551 
alignment, with those identical in all nine sequences in uppercase, whilst residues conserved in at 552 
least seven of nine alleles are shown in lowercase. The positions of conserved cysteine residues are 553 
boxed and predicted N-linked glycosylation sites (score >0.5; NetNGlyc 1.0 Server, 554 
http://genome.cbs.dtu.dk/) are highlighted in grey. The position and length of signal peptides in 555 
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each polypeptide were predicted using SignalP Server 4.1 (http://genome.cbs.dtu.dk/) and is 556 
indicated by underlining. 557 
Fig. 4. Phylogenetic analysis of the combined ORF50-ORF75-Ov9.5 nucleotide sequences was 558 
performed using the approach described in Fig. 2 for the 21 samples for which sequence was 559 
obtained from all three loci.  Branch lengths are not proportional to genetic distance in this figure. 560 
Bootstrap values (percentage of 500 replicates) are given on the left of the respective nodes, except 561 
for two terminal nodes where they are placed to the right of the node. The combined sequences are 562 
named according to the sample designations in Table 1. The genotypes of the three loci for each 563 
sample are indicated to the right of the tree and assignment of OvHV-2 strain type is given on the 564 
right of the figure.  Samples with identical genotypes are boxed whilst the Ov9.5 clades are 565 
separated by thick lines. 566 
 567 
Ov9 stop                                                                                                                                                           Ov9.5-L1  
|:::||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 
          Ov9.5-L2                                                                                        Ov9.5 stop        Exon4 
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                      *        20         *        40         *        $60         *        80         *       100       
Ov9p5*0101  MGVRRLLVVGSLGLILTLCLQPQQGTSLHRTVKETILSLKFILNLTNCFNVTYNDHSGCSNATLGDK-TPGLPCIQCFNISLTNNNSTECNLKGPHLLEV    
Ov9p5*0201  MGFSRLLPVLGLSLLLTLCIHLQNGHGVRHTLKESITILKSNSNLADCVILIYNGNGNCSNTTLGDPKTVGLPCRNCFNITLKNNN-TDCLQKEQELYEV    
Ov9p5*0202  MGFSRLLSVLGLSLLLTLCIHLQNGHGVRHTLKESITILKSNSNLADCVILIYNGNGNCSNTTLGDPKTVGLPCRNCFNITLKNNN-TDCLQKEQELYEV    
Ov9p5*0203  MGFSRLLPVLGFSLLLTLCIHLQNGHGVRHTLKESITILKSNSNLADCVILIYNGNGNCSNTTLGDPKTVGLPCRNCFNITLKNNN-TDCLQKEQELYEV    
Ov9p5*0301  MGFSRLLPVLGLSLLLTLCIHLQNGHGVRHTLKESIMIIKSNLNLSDCVKITYNGNSNCSNATLGDQGNLGLPCRDCLNITLNKNN-TDCLEKEHELNEV    
Ov9p5*0401  MGFSRLLPVLGLSLLLTLCIHLQNGHGVRHTLKESITILKSNSNLADCVKLIYNGNGNCSNTTLGDPKTVGLPCRDCFNITLKNNN-TDCLQKEQELYEV    
Ov9p5*0501  MGYCKLFGVLSLGILLTLCLQPQQGNGVHRTLKESIVTLKSILNWTRCINLTYTGGPDCANTTLGDKHEPGLPCRFCFNITLLQN-STECLEKEHALLDV    
Ov9p5*0502  MGYCKLFGVLSLGILLTLCLQPQQGNGVHRTLKESIVTLKSILNWTRCINLTYTGGPDCANTTLGDKHEPGLPCRFCFNITLLQN-STECLEKEHALLDV    
Ov9p5*0503  MGYCKLFGVLSLGILLTLCLQPQQGNGVHRTLKESIVTLKSILNWTRCINLTYTGGPDCANTTLGDKHEPGLPCRFCFNITLLQN-STECLEKEHALLDV    
Conserved   MG   L  Vl L  LLTLC   Q G gv  TlKEsI  LKs  N   C    Y g   C NtTLGD    GLPCr CfNItL  N  T Cl Ke  L  V                                                                    
                                                                                 
                      *       120         *       140         *       160        
Ov9p5*0101  VTGPHRNTRHKSL-EKSDLAANVTCKEFGNETTPDILGYWLTVMQRTYHNIHAKKAGKPLQ   
Ov9p5*0201  QHRTDRNVRKQRLTSTNDFASNVTCEQFGNHTTEDILGYWLSLLQRKYHNLYCK-LGVNCQ   
Ov9p5*0202  QHRTDRNVRKQRLTSTNDFASNVTCEQFGNHTTEDILGYWLSLLQRKYHNLYCK-LGVNCQ   
Ov9p5*0203  QHRTDRNVRKQRLTSTNDFASNVTCEQFGNHTTEDILGYWLSLLQRKYHNLYCK-LGVNCQ   
Ov9p5*0301  TKRTDRNTRKQNLLRSSDFARNVTCEQFGNHTTVEILDYWLSLLQRKYHNLYCK-PGVDCQ   
Ov9p5*0401  QYRTDRNVRKQRLTSTNDYASNVTCAQFGNHTTEDILGYWLSLLQRKYHNLYCK-PGVDCQ   
Ov9p5*0501  LTQTDRNTHRHSL-QKHEITANVTCDQFGHHDKKEVLEYWLSLLMKNYHNEHAKKAGIRLQ   
Ov9p5*0502  LTQTDRNTHRHSL-QKHEITANVTCDQFGHRDKKEVLEYWLSLLMKNYHNEHAKKAGIRLQ   
Ov9p5*0503  LTQTDRNTHRHSL-QKHEITANVTCDQFGHHDKKDVLEYWLSLLMKNYHNVHAKKAGIRLQ   
Conserved      tdRN     L        NVTC qFG h     L YWLsll   YHN   K  G   q 
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Figure
                                                                                                     126150   
Ov9.5*01 CTAGTAAGGTGTCATTTCGAAAACGAGACATTTAAACCTTGCGGGTGCCGACAAACCACAAAGTAGCTTTAAGGAAGTGAGCTTAATAGTGAAAACCTTA 
    Ov9  :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
OV9.5*02 CTAGTAAGGTGTCATTTCGAAAACGAGACATTTAAACCTTGCGGGTGCCGACAAACCACAAAGTAGCTTTAAGGAAGTGAGCTTAATAGTGAAAACCTTA 
                                                                                                      126160  
           
                                                                        Ov9.5-L1                    126250   
Ov9.5*01 AAGTTTGACTTTCCTCCAAACCACATTTTATTAACTACTTACTAAATCTAATCTAATAAAGACACATGCATCAAACTCTATTAAGTGTCTCGACTTTTTA 
         :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
OV9.5*02 AAGTTTGACTTTCCTCCAAACCACATTTTATTAACTACTTACTAAATCTAATCTAATAAAGACACATGCATCAAACTCTATTAAGTGTCTCGACTTTTTA 
                                                                                                     126260  
 
                   Ov9.5-L2                                                                         126350   
Ov9.5*01 TTAATGAAAAACTGGCCACATAAATAAGAGGTTTTCTGGTTTTTAAACTTGATGACAATTTCATGTATCTTCGGGCTTGTACAGTAGTCAAGTATCTGGA 
         :::::::::::::::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::::::::::::::::::::::: 
OV9.5*02 TTAATGAAAAACTGGCCACATAAATAAGAGGTTTTCTGGTTTTTAAACTTGATAACAATTTCATGTATCTTCGGGCTTGTACAGTAGTCAAGTATCTGGA 
                                                                                                     126360 
 
                                                   Exon 4                                            126450   
Ov9.5*01 TTTAAGACGCCTGTTCGAAGGTATTTATTGGAGAGGCTTTCCGGCTTTTTTTGCATGTATGTTGTGGTAAGTCTGCAATATATTAAAACATTTTGTTAAA 
         :: :::: :: ::::   :::::::::::::  :   ::: :  :    ::   :: :: :::::::::  :::: :: ::: ::::: :  :   :::  
OV9.5*02 TTCAAGATGCTTGTTTAGAGGTATTTATTGGCAA---TTTACCCCGAACTTGCAATATAAGTTGTGGTATTTCTGTAAGATAGTAAAATAACTGTGTAAG 
                                                                                               126450   
 
                                                                                                      126550 
Ov9.5*01 CACGTATTGATCATAATGTAAGTTT--TTCCAGCATATGTTAATCATAATGGGGATGGAGCTTTCAACAACAGTGCTAAACACACCAATAACTTCATTTC 
          :  ::: ::: ::: :::::::    :  :: :::    ::: :: : :::      :::: :::: :  ::    ::::::::   :: ::::::: : 
OV9.5*02 AATTTATCGATTATATTGTAAGTGACATGGCATCAT----TAACCAAATTGGCTGGCTAGCTGTCAATAT-AGACACAAACACACTG-TAGCTTCATTAC 
                                                                                                     126550   
 
                                                                        Exon 3                         126650 
Ov9.5*01 CCAAGTGAATGGTTGAAATAATAATAAAAAAACTCTTACCCGCTGCATTACAGTTAACCAGTAACCCAAAATATCAGGAGTAGTTTCATTTCCAAACTCT 
           :: ::::      ::: :: : :::::::  :::::::: ::: : :: : : : :::::: :::::::: ::    ::::: :  :: :: :: : : 
OV9.5*02 T-AACTGAAGA---AAAACAACATTAAAAAA--TCTTACCCTCTGTAATAAACTCAGCCAGTAGCCCAAAATCTCTTCTGTAGTATGGTTGCCGAATTGT 
                                                                                                 126640       
 
                                                       Exon 3                                    126740       
Ov9.5*01 TTACAAGTAACATTAGCAGCTAAGTCACTTTTTTCAAGT--GAC-TTG-TGGCGTGTGTTTCGATGAGGTCCAGTGACAACCTCCAATAGATGTGGACCT 
           :::::: ::::::  :::  ::::  ::: : :  ::  ::: ::: : ::::   ::::: :  : :: :     ::::::  : :: :   :  :  
OV9.5*02 GCACAAGTCACATTACTAGCATAGTCG-TTTGTGCTTGTAAGACGTTGCTTGCGTACATTTCGGTCGGTTCGATATTGAACCTCGTAAAGTTCCTGTTCC 
                                                                                                  126740      
 
                                      Exon 3                                                     126840       
Ov9.5*01 TTCAGATTACACTCAGTGGAGTTGTTGTTTGTTAGGGAAATGTTGAAACACTGAATGCAAGGCAATCCAGGTGTCTGAAAAACATTAGATACATATAAGT 
         ::  :   ::: :: :::   ::::: ::  : :: :  :::::::: :: :   : :: ::::: ::    ::::  :::::::         : : :  
OV9.5*02 TTTTGTAGACAATCTGTG---TTGTTATTCTTCAGAGTTATGTTGAAGCAATCCCTACAGGGCAACCCTACAGTCTAGAAAACAT---------AAAGGC 
                                                                                                    126830    
 
                                                                                             Exon 2  126940   
Ov9.5*01 TTTGCTATAAACACTACATA-CAATCTATCGCATACAGTAAATTACATATAATATAAAATAGAGACTATATACCTACTT-TG--TCACCTAGTGTAGCAT 
         :::  ::: :: :  :  :: :  :  ::::           :::: ::::  :  ::  :  :: :  : :: ::: : ::  ::::::: ::::: :: 
OV9.5*02 TTT--TATCAAGATCAGTTAGCCCTTCATCG-----------TTACTTATACAA--AAGCAATGAATGCAAACTTACCTGTGGATCACCTAATGTAGTAT 
                                                                                                 126910         
 
                   Exon 2                                                                             127040 
Ov9.5*01 TTGAGCAACCAGAGTGATCATTGTAGGTTACATTCTACAAAAAAA-ACATATTGGTTACTACACTTAAGCAGTGATTCAAGATATAAATTTTAATGTATT 
         : :::::   :  :: : :::::::  : :  ::::: :: :::: : ::: :      :::::: :::  :::: :     ::: :::    : :: :  
OV9.5*02 TCGAGCAGTTACCGTTACCATTGTAAATCAATTTCTAGAAGAAAATAAATAAT------TACACTAAAGTGGTGAATAGCACTATGAATAAACAGGTGTC 
                                                                                                     127010   
 
                                                                     Exon 1                          127140 
Ov9.5*01 ATAGAATAAGTTGTATACATATACTTACAAAACAGTTGGTTAAATTGAGGATAAACTTTAATGATAAAATAGTTTCCTTCACAGTACGATGTAGACTTGT 
         : :   ::     ::::  ::::::::::: ::::: ::: :::::   : ::  :::::::  :  :::: :::: ::::  ::: :: : :  :     
OV9.5*02 ACATCTTAT----TATAGGTATACTTACAACACAGTCGGTCAAATTTGAGTTACTCTTTAATATTGTAATACTTTCTTTCAAGGTATGACGAACTCCATG 
                                                                                               127100         
 
                                    Exon 1                                                    127230          
Ov9.5*01 TCCTTGCTGAGGTTGGAGACACAGGGTCAGTATAAGGCCGAGGCTTCCCACAACGAGCAACCTACGAACACCCATGCTGAGTGT--TCCTATGTCCTCTT 
         ::: : :::: : :: :: :: :  :::: :: :::::  :::: :  ::::  ::: :::::    : :::::::::: ::::  ::: :   ::  :: 
OV9.5*02 TCCATTCTGAAGGTGAAGGCATAATGTCAATAAAAGGCTAAGGCCTAGCACAGGGAGTAACCTGGAGAAACCCATGCTGTGTGTGTTCCCAGCGCC--TT 
                                                                                               127200         
 
                       Ov9.5-R2                Ov9.5-R1                                     127330          
Ov9.5*01 CCACAATATCTGGAGTTTATCAGGGTTCTTATACTGCTTTATACCATGTACTTACCCTCAACATTTTTGTAAGTATCGAAATAAGTAAAAATGAAAGTAT 
         ::::::::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
OV9.5*02 CCACAATATCTGGAGTTTATCAGGGTTTTTATACTGCTTTATACCATGTACTTACCCTCAACATTTTTGTAAGTATCGAAATAAGTAAAAATGAAAGTAT 
                                                                                                 127300       
 
                                                                                              127430          
Ov9.5*01 TCGCCTTTATCAGACATAATTGGATTTACTGGACCAAGGGTCAGATCAAAGCATGGGATGAGTAACTTCGGGTTAGGTTGACTTACTAAGAACTTAGGCA 
         : :::::::::::::::: :::::::::::::::::::::::::::::::: :::::::::::::::::::::::::::::::::::::::::::::::: 
OV9.5*02 TAGCCTTTATCAGACATAGTTGGATTTACTGGACCAAGGGTCAGATCAAAGTATGGGATGAGTAACTTCGGGTTAGGTTGACTTACTAAGAACTTAGGCA 
                                                                                                 127400       
 
                                                                                              127530          
Ov9.5*01 TGAATTTCCGGGAGAAAGTTATCAACACTACTTATCTATGAATAAAGACAGACTACAATCATTTGTATTATGAAGCTTTTATTAGCAAAATATTTACAAG 
         ::::::::::::::::::::::::::::::::::::::::::::: :::::::::: ::::::::::::::::::::::::::::::::::::::::::: 
OV9.5*02 TGAATTTCCGGGAGAAAGTTATCAACACTACTTATCTATGAATAAGGACAGACTACTATCATTTGTATTATGAAGCTTTTATTAGCAAAATATTTACAAG 
                                                                                                 127500       
 
                                                                                              127630          
Ov9.5*01 TTTGGGGTTACGTCACTCAGATAACTGTATCTAGCAACTAGCAGTTAAAGGTTTCAGGTTTCCAGTCGACAGGATTAGTGGTTTAATGCTATTCCATTAA 
         :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::::: 
OV9.5*02 TTTGGGGTTACGTCACTCAGATAACTGTATCTAGCAACTAGCAGTTAAAGGTTTCAGGTTTCCAGTCGACGGGATTAGTGGTTTAATGCTATTCCATTAA 
                                                                                                 127600       
 
                                                                                              127730          
Ov9.5*01 TGCCAACATGACAGTGCAAAGCACAAGAATTGTTGCATGACTTCAGCAGCATCAAGAGACTTCTTTATTTGGTCGCATTAAGTGCCTGTTGAATTATTGC 
         ::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::::::: :::::::::                ::::::::::: 
OV9.5*02 TGCCAACATGACAGTGCAAAGCACAAGAATTGTTGCATGACTTCAGCAGCATCAATAGACTTCCTTATTTGGT----------------TGAATTATTGC 
                                                                                                       127690 
 
                                                                                              127830          
Ov9.5*01 TATTGTTGTTCCCAGTAGCGAGGATAACCCTGAAAGCAAATTGAATAATAGTAAACAACTATTCATAATACCATCTACAACTCATATTTCCAGACAGTTT 
         : :::  :    :::: : ::::: ::::::::::::::::: ::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
OV9.5*02 TCTTGAGGGCATCAGTTGTGAGGAGAACCCTGAAAGCAAATTCAATAATAGTAAACAACTATTCATAATACCATCTACAACTCATATTTCCAGACAGTTT 
                                                                                                       127790 
 
                                                                                    127920    
Ov9.5*01 ACTGATAGCAGATACTAAGCTCACAGCATTCACTAAATCTGGTTGGTAAAATCAAAATGCATATAATAAAATGGCAATACTCAC 
         ::::::::::::::::::::::::::::::::: ::::::::::::::::::::::::::: ::::::::::::::::::::::  Ov10 
Ov9.5*02 ACTGATAGCAGATACTAAGCTCACAGCATTCACAAAATCTGGTTGGTAAAATCAAAATGCACATAATAAAATGGCAATACTCAC 
                                                                                   127870     
 
 
 
Supplementary Fig. S1. Alignment of the Ov9–Ov10 intergenic region between the two OvHV-2 genome sequences. The segment of 
the Hart et al. (2007) sequence (AY839756) is labeled Ov9.5*01 while the Taus et al. (2007) sequence (DQ198083) is labeled 
Ov9.5*02. The predicted termination codons of the Ov9, Ov9.5 and Ov10 genes are boxed, while the putative coding exons of the 
Ov9.5 alleles are shaded within the alignment and named above it.  Identical positions within the alignment are indicated by colons (:), 
while gaps inserted to maximize similarity are shown by dashes (-). The positions of PCR primers designed to amplify the Ov9.5 
region are indicated by underlining in each sequence, with primer names and polarities given above the alignment. 
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Russell et al., 2014. 
Supplementary Fig. S2. 
UK map showing regional assignment of Ov9.5 genotypes among MCF-positive samples. 
Ov9.5 genotypes are represented by symbols as shown in the key on the right of the map, 
while the genotypes found in the MCF outbreaks listed in Table 1 are shown as numbered 
yellow ellipses as follows: 1, Outbreak L (head & eye); 2, Farm A (alimentary); 3, Farm E 
(alimentary); 4, Outbreak B (head & eye); 5, Outbreak A (alimentary). 
No samples from MCF cases in Scotland or Northern Ireland were used in this study.  
 
